Fusion Antibodies (LON:FAB) Shares Up 14.1% – Should You Buy?

Fusion Antibodies plc (LON:FAB) shares shot up 14.1% during mid-day trading on Tuesday . The company traded as high as GBX 11 and last traded at GBX 10.55. Approximately 1,644,497 shares traded hands during mid-day trading, an increase of 288% from the average session volume of 424,310 shares. The stock had previously closed at GBX 9.25.

Fusion Antibodies Trading Down 2.9%

The company has a quick ratio of 2.36, a current ratio of 2.82 and a debt-to-equity ratio of 20.41. The stock has a market capitalization of £13.67 million, a PE ratio of -7.28 and a beta of 1.24. The business’s 50-day moving average is GBX 10.83 and its two-hundred day moving average is GBX 12.11.

Fusion Antibodies (LON:FAB) last posted its quarterly earnings data on Monday, September 14th. The company reported GBX (1.20) earnings per share for the quarter. Fusion Antibodies had a negative net margin of 54.45% and a negative return on equity of 97.87%. On average, analysts anticipate that Fusion Antibodies plc will post -129.9999875 earnings per share for the current fiscal year.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.